Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
OPKO Health Inc has a consensus price target of $2.65 based on the ratings of 7 analysts. The high is $3 issued by HC Wainwright & Co. on April 7, 2025. The low is $1.6 issued by Jefferies on October 31, 2025. The 3 most-recent analyst ratings were released by Barrington Research, Jefferies, and Barrington Research on March 2, 2026, October 31, 2025, and October 30, 2025, respectively. With an average price target of $1.78 between Barrington Research, Jefferies, and Barrington Research, there's an implied 59.23% upside for OPKO Health Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for OPKO Health (NASDAQ:OPK) was reported by Barrington Research on April 29, 2026. The analyst firm set a price target for $0.00 expecting OPK to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for OPKO Health (NASDAQ:OPK) was provided by Barrington Research, and OPKO Health downgraded their market perform rating.
The last upgrade for OPKO Health Inc happened on June 29, 2023 when Barrington Research raised their price target to $2. Barrington Research previously had a market perform for OPKO Health Inc.
The last downgrade for OPKO Health Inc happened on April 29, 2026 when Barrington Research changed their price target from N/A to N/A for OPKO Health Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of OPKO Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for OPKO Health was filed on April 29, 2026 so you should expect the next rating to be made available sometime around April 29, 2027.
While ratings are subjective and will change, the latest OPKO Health (OPK) rating was a downgraded with a price target of $0.00 to $0.00. The current price OPKO Health (OPK) is trading at is $1.12, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API
Market data provided by Benzinga APIs
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

| Buy Now | Get Alert | ||||||
|---|---|---|---|---|---|---|---|
| 04/29/2026 | Buy Now | — | Barrington Research | — | Downgrade | Outperform → Market Perform | Get Alert |
| 03/02/2026 | Buy Now | 33.93% | Barrington Research | $2.25 → $1.5 | Maintains | Outperform | Get Alert |
| 11/20/2025 | Buy Now | — | JP Morgan | — | Initiates | → Neutral | Get Alert |
| 10/31/2025 | Buy Now | 42.86% | Jefferies | $2 → $1.6 | Downgrade | Buy → Hold | Get Alert |
| 10/30/2025 | Buy Now | 100.89% | Barrington Research | $2.25 → $2.25 | Maintains | Outperform | Get Alert |
| 05/01/2025 | Buy Now | 100.89% | Barrington Research | $2.25 → $2.25 | Maintains | Outperform | Get Alert |
| 04/25/2025 | Buy Now | — | JP Morgan | — | Initiates | → Neutral | Get Alert |
| 04/07/2025 | Buy Now | 167.86% | HC Wainwright & Co. | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 03/19/2025 | Buy Now | 167.86% | HC Wainwright & Co. | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2025 | Buy Now | 167.86% | HC Wainwright & Co. | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2025 | Buy Now | 100.89% | Barrington Research | $2.25 → $2.25 | Maintains | Outperform | Get Alert |
| 03/03/2025 | Buy Now | 167.86% | HC Wainwright & Co. | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2025 | Buy Now | 100.89% | Barrington Research | $2.25 → $2.25 | Maintains | Outperform | Get Alert |
| 01/08/2025 | Buy Now | 167.86% | HC Wainwright & Co. | $3 → $3 | Maintains | Buy | Get Alert |
| 11/08/2024 | Buy Now | 100.89% | Barrington Research | $2.25 → $2.25 | Maintains | Outperform | Get Alert |
| 09/26/2024 | Buy Now | 167.86% | HC Wainwright & Co. | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 09/20/2024 | Buy Now | 100.89% | Barrington Research | $2.25 → $2.25 | Maintains | Outperform | Get Alert |
| 09/17/2024 | Buy Now | 167.86% | Piper Sandler | $3 → $3 | Reiterates | Overweight → Overweight | Get Alert |
| 09/17/2024 | Buy Now | 167.86% | HC Wainwright & Co. | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2024 | Buy Now | 100.89% | Barrington Research | $1.5 → $2.25 | Maintains | Outperform | Get Alert |
| 07/18/2024 | Buy Now | 167.86% | Piper Sandler | $5 → $3 | Maintains | Overweight | Get Alert |
| 05/08/2024 | Buy Now | 167.86% | HC Wainwright & Co. | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2024 | Buy Now | 167.86% | HC Wainwright & Co. | → $3 | Reiterates | Buy → Buy | Get Alert |
| 04/01/2024 | Buy Now | 33.93% | Barrington Research | $1.5 → $1.5 | Maintains | Outperform | Get Alert |
| 04/01/2024 | Buy Now | 346.43% | Piper Sandler | → $5 | Reiterates | Overweight → Overweight | Get Alert |
| 02/28/2024 | Buy Now | 167.86% | HC Wainwright & Co. | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | 33.93% | Barrington Research | $2 → $1.5 | Maintains | Outperform | Get Alert |
| 08/07/2023 | Buy Now | 167.86% | HC Wainwright & Co. | → $3 | Reiterates | Buy → Buy | Get Alert |
| 06/29/2023 | Buy Now | 78.57% | Barrington Research | → $2 | Upgrade | Market Perform → Outperform | Get Alert |